Shakti Nagpal

Dr. Shakti Nagpal

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
TKTatyana Kovshova
Tatyana Kovshova
NONadezhda Osipova
Nadezhda Osipova
AAAnna Alekseeva
Anna Alekseeva
JMJulia Malinovskaya
Julia Malinovskaya
ABAlexey Belov
Alexey Belov
SGSvetlana Gelperina
Svetlana Gelperina
Targeted delivery of doxorubicin still poses a challenge with regards to the quantities reaching the target site as well as the specificity of the uptake. In the present approach, two colloidal nanocarrier systems, NanoCore-6.4 and NanoCore-7.4, loaded with doxorubicin and characterized by different drug release behaviors were evaluated in vitro and in vivo. The nanoparticles utilize a specific surface design to modulate the lipid corona by attracting blood-borne apolipoproteins involved in the endogenous transport of chylomicrons across the blood–brain barrier. When applying this strategy, the fine balance between drug release and carrier accumulation is responsible for targeted delivery. Drug release experiments in an aqueous medium resulted in a difference in drug release of approximately 20%, while a 10% difference was found in human serum. This difference affected the partitioning of doxorubicin in human blood and was reflected by the outcome of the pharmacokinetic study in rats. For the fast-releasing formulation NanoCore-6.4, the AUC0→1h was significantly lower (2999.1 ng × h/mL) than the one of NanoCore-7.4 (3589.5 ng × h/mL). A compartmental analysis using the physiologically-based nanocarrier biopharmaceutics model indicated a significant difference in the release behavior and targeting capability. A fraction of approximately 7.310–7.615% of NanoCore-7.4 was available for drug targeting, while for NanoCore-6.4 only 5.740–6.057% of the injected doxorubicin was accumulated. Although the targeting capabilities indicate bioequivalent behavior, they provide evidence for the quality-by-design approach followed in formulation development.

1 August 2020 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SNShakti Nagpal
Shakti Nagpal
SBSvenja Braner
Svenja Braner
HMHarshvardhan Modh
Harshvardhan Modh
ATAda Xi Xin Tan
Ada Xi Xin Tan
MMMarc-Phillip Mast
Marc-Phillip Mast
MWMatthias G. Wacker
Matthias G. Wacker

1 October 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HMHarshvardhan Modh
Harshvardhan Modh
DFDaniel Juncheng Fang
Daniel Juncheng Fang
YOYi Hsuan Ou
Yi Hsuan Ou
JYJia Ning Nicolette Yau
Jia Ning Nicolette Yau
TKTatyana Kovshova
Tatyana Kovshova
MWMatthias G. Wacker
Matthias G. Wacker

11 January 2020
Verified
Book Chapter
Closed access
PDF file
GSGautam Singhvi
Gautam Singhvi
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SNShakti Nagpal
Shakti Nagpal
SDSunil Kumar Dubey
Sunil Kumar Dubey
RSRanendra Narayan Saha
Ranendra Narayan Saha

12 November 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
SNShakti Nagpal
Shakti Nagpal
TPThilagavathi Palaniappan
Thilagavathi Palaniappan
JWJiong-Wei Wang
Jiong-Wei Wang
MWMatthias G. Wacker
Matthias G. Wacker

3 July 2021 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
ATAarzoo Thakur
Aarzoo Thakur
ZTZhiyuan Tan
Zhiyuan Tan
TKTsubasa Kameyama
Tsubasa Kameyama
EEEman El-Khateeb
Eman El-Khateeb
SNShakti Nagpal
Shakti Nagpal
Chukwunonso Kingsley NwabufoChukwunonso Kingsley Nwabufo
Chukwunonso Kingsley Nwabufo
A reliable, rapid, and effective bioanalytical method is essential for the determination of the pharmacokinetic, pharmacodynamic, and toxicokinetic parameters that inform the safety and efficacy profile of investigational drugs. The overall goal of bioanalytical method development is to elucidate the procedure and operating conditions under which a method can sufficiently extract, qualify, and/or quantify the analyte(s) of interest and/or their metabolites for the intended purpose. Given the difference in the physicochemical properties of small and large molecule drugs, different strategies need to be adopted for the development of an effective and efficient bioanalytical method. Herein, we provide an overview of different sample preparation strategies, analytical platforms, as well as procedures for achieving high-throughput for bioanalysis of small and large molecule drugs.